COX-2, MMP-9, and Noguchi Classification Provide Additional Prognostic Information about Adenocarcinoma of the Lung: A Study of 117 Patients from Brazil

American Journal of Clinical Pathology

Volumn 121, Issue 1, 2004, Pages 78-86

  Yamaguchi, Nise H ^a   Lichtenfels, Ana J De F C ^a   Demarchi, Lea M M ^b   Da Silva, Alecsander P ^a   Garippo, Ana L ^a   Alves, Venancio F A ^a   Michelin, Carolina ^b   Azevedo, Pedro M ^b   Moya, Tatiana ^b   Takagaki, Tereza ^a   Saldiva, Paulo H ^a   Vollmer, Robin T ^c,d   Capelozzi, Vera L ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Institute of Advances in Medicine   (Brazil)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Cox 2; Immunohistochemistry; Lung cancer; MMP 9; Morphometry; Prognostic markers

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE B;

ADULT; AGED; ARTICLE; BRAZIL; CANCER CLASSIFICATION; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORPHOMETRICS; NOGUCHI CLASSIFICATION; PAPILLARY CARCINOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; STAINING; SURVIVAL TIME;

EID: 9144221378     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/P2CDFGU1U7CLV5YR     Document Type: Article

References (50)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-1717.
2. Liotta LA, Rao CN, Barsky H. Tumor invasion and the extracellular matrix. Lab Invest. 1983;49:636-649.
3. Aznavoorian S, Murphy NA, Stetler-Stevenson WG, et al. Molecular aspects of tumor cell invasion and metastasis. Cancer. 1993;71:1368-1383.
4. Strauss GM, Kwiatkowski DJ, Harpole DH, et al. Molecular and pathologic markers in stage I non-small cell carcinoma of the lung. J Clin Oncol. 1995;13:1265-1279.
5. Harpole DH, Richards WG, Herndon JE, et al. Angiogenesis and molecular biologic substaging in patients with stage 1 non-small cell lung cancer. Ann Thorac Surg. 1996;61:1470-1476.
6. Graziano SL. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer. 1997;17(suppl 1): S37-S58.
7. Carvalho PEO, Antonângelo L, Bernardi FDC, et al. Useful prognostic panel markers to express the biological tumor status in resected lung adenocarcinomas. Jpn J Clin Oncol. 2000;30:478-486.
8. Demarchi LMM, Reis MM, Palomino SAP, et al. Prognostic values of stromal density and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Mod Pathol. 2000;13:511-520.
9. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073.
10. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
11. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716.
12. McLemore TL, Hubbard WC, Litterest CL, et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 1988;48:3140-3147.
13. Hubbard WC, Alley MC, Gray GN, et al. Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res. 1989;49:826-832.
14. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998;58:3761-3764.
15. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998;58:4997-5001.
16. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res. 1999;5:1001-1005.
17. Ochai M, Oguri T, Isobe T, et al. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res. 1999;90:1338-1343.
18. Watkins DN, Lenzo JC, Segal A, et al. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur Respir J. 1999;14:412-418.
19. Hasturk S, Kemp B, Kalapurakal SK, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer. 2002;94:1023-1031.
20. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 2000;30:73-81.
21. Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res. 2000;6:4739-4744.
22. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer. 2000;89:2637-2645.
23. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage 1 non-small cell lung cancer. Clin Cancer Res. 2001;7:861-867.
24. Brabender J, Park J, Metzger R, et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg. 2002;235:440-443.
25. Niki T, Kohno T, Iba S, et al. Frequent co-localization of Cox-2 and laminin-5 γ2 chain at the invasive front of early-stage lung adenocarcinomas. Am J Pathol. 2002;160:1129-1141.
26. Urbanski SJ, Edwards DR, Maitland A, et al. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer. 1992;66:1188-1194.
27. Brown PD, Bloxidge RE, Stuart NSA, et al. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J Natl Cancer Inst. 1993;85:574-578.
28. Canete-Soler R, Litzky L, Lubensky I, et al. Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization. Am J Pathol. 1994;144:518-527.
29. Wilson CL, Matrisian LM. Matrylisin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol. 1996;28:123-136.
30. Nawrocki B, Polette M, Marchand V, et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer. 1997;72:556-564.
31. Kodate M, Kasai T, Hashimoto H, et al. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int. 1997;47:461-469.
32. Gonzalez-Avila G, Iturria C, Vadillo F, et al. 72-kd (MMP-2) and 92-kd (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells. Pathobiology. 1998;66:5-16.
33. Suzuki M, lizasa T, Fujisawa T, et al. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small cell lung cancer. Invasion Metastasis. 1998;18:134-141.
34. lizasa T, Fujisawa T, Suzuki M, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res. 1999;5:149-153.
35. Fujise N, Nanashima A, Taniguchi Y, et al. Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer. 2000;27:19-26.
36. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 2000;6:2349-2355.
37. Passlick B, Sienel W, Seen-Hibler R, et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res. 2000;6:3944-3948.
38. Thomas F, Khokha R, Shepherd FA, et al. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol. 2000;190:150-156.
39. Kumaki F, Matsui K, Kawai T, et al. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol. 2001;159:2125-2135.
40. Shou Y, Hirano T, Gong Y, et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer. 2001;85:1706-1712.
41. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 2002;29(suppl 4):78-86.
42. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5:138-146.
43. Pinto CA, Carvalho PE, Antonângelo L, et al. Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung. Clin Cancer Res. 2003;9:3098-3104.
44. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer. 1995;75:2844-2852.
45. Cox DR, Oakes D. Analysis of Survival Data. London, England: Chapman and Hall; 1990.
46. Sorenson JB, Hirsch FR, Olsen J. The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. Cancer. 1988;62:361-367.
47. Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Washington, DC: Armed Forces Institute of Pathology; 1995. Atlas of Tumor Pathology. Third series, Fascicle 13.
48. Eto T, Suzuki H, Honda A, et al. The changes of the stromal elastotic framework in the growth of peripheral lung adenocarcinomas. Cancer. 1996;77:646-656.
49. Goldstein NS, Mani A, Chmielewski G, et al. Prognostic factors in T1 N0 M0 adenocarcinomas and bronchioloalveolar carcinomas of the lung. Am J Clin Pathol. 1999;112:391-402.
50. Terasaki H, Niki T, Matsuno Y, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components. Am J Surg Pathol. 2003;27:937-951.